Key Developments: Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

140.30EUR
11:35am EDT
Change (% chg)

€0.35 (+0.25%)
Prev Close
€139.95
Open
€139.20
Day's High
€143.05
Day's Low
€139.05
Volume
2,242,630
Avg. Vol
2,308,735
52-wk High
€145.85
52-wk Low
€91.51

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bayer says China study confirms Eylea improves vision
2:30am EDT 

Bayer AG:Says new phase 3 study in China confirms vision improvement for patients with wet age-related macular degeneration when receiving aflibercept solution (Eylea) for intravitreal injection.Says has submitted an application for marketing authorization of aflibercept solution for injection for treatment of patients with wet amd to China food and drug administration.  Full Article

Bayer AG issues EUR 1.3 billion in hybrid capital
Sunday, 29 Mar 2015 08:00pm EDT 

Bayer AG:Issued a hybrid bond with a total volume of EUR 1.3 billion.Proceeds will be used for general corporate purposes.  Full Article

Bayer AG receives approval of Gadovist injection in Japan-Reuters
Thursday, 26 Mar 2015 03:05am EDT 

Bayer AG:Receives approval for Gadovist (gadobutrol) injection in Japan-Reuters.  Full Article

Bayer AG submits Eylea for new treatment in EU
Wednesday, 11 Mar 2015 03:34am EDT 

Bayer AG:Submits aflibercept solution for intravitreal injection for treatment of myopic choroidal neovascularization in EU.  Full Article

Bayer AG to float MaterialScience by mid-2016 at latest
Tuesday, 10 Mar 2015 08:00pm EDT 

Bayer AG:Says carve-out of MaterialScience is to be completed by August 31, and company floated on stock market by mid-2016 at latest.Plans to decide between an IPO and spin-off in H2 2015.  Full Article

Bayer AG gives FY 2015 outlook in line with analysts' estimates
Wednesday, 25 Feb 2015 07:00pm EST 

Bayer AG:Is planning sales in region of 46 billion euros for FY 2015.Plans to raise FY 2015 EBITDA before special items by a low- to mid-teens percentage, allowing for expected positive currency effects of about 2 pct.FY 2015 revenue estimate 45.612 billion euros - Thomson Reuters I/B/E/S.FY 2014 EBITDA before special items of 8,812 million euros.FY 2015 EBITDA estimate 10.059 billion euros - Thomson Reuters I/B/E/S.  Full Article

Bayer AG proposes FY 2014 dividend
Tuesday, 24 Feb 2015 07:00pm EST 

Bayer AG:Proposes increased dividend for FY 2014 of 2.25 euros per share (2013: 2.10 euros per share).  Full Article

Bayer AG says Adempas approved in Japan for treatment of pulmonary arterial hypertension
Thursday, 19 Feb 2015 07:00pm EST 

Bayer AG:Adempas approved in Japan for the treatment of pulmonary arterial hypertension.  Full Article

Bayer says FDA approves gadavist (gadobutrol) injection
Monday, 5 Jan 2015 02:30am EST 

Bayer AG:Says FDA approves gadavist (gadobutrol) injection as first magnetic resonance contrast agent for pediatric patients less than 2 years of age.  Full Article

Bayer AG to divest equine assets to Merial, Inc.
Tuesday, 16 Dec 2014 07:00pm EST 

Bayer AG:Enters into a definitive agreement to sell its equine products Legend/Hyonate (hyaluronate sodium) and Marquis (ponazuril) to Merial, Inc.The deal is expected to close in the first quarter 2015 subject to customary conditions, including relevant merger control clearance.  Full Article

BRIEF-Bayer says China study confirms Eylea improves vision

* Says new phase 3 study in china confirms vision improvement for patients with wet age-related macular degeneration when receiving aflibercept solution (Eylea) for intravitreal injection

Search Stocks